Atypical antipsychotics (drug interactions)

DEFINITION: Drug used to treat schizophrenia, psychosis, mania, depression, and agitation. Sometimes called second-generation antipsychotics.

INTERACTIONS: Ginkgo, glycine, St. John’s wort

DRUGS IN THIS FAMILY: Olanzapine (Zyprexa), risperidone (Risperdal), clozapine (Clozaril), quetiapine (Seroquel), ziprasidone (Geodon), aripiprazole (Abilify), paliperidone (Invega), lurasidone (Latuda), asenapine (Saphris), iloperidone (Fanapt)

St. John’s Wort

Effect: Possible Harmful Interaction

The herb St. John’s wort might reduce levels of these medications in the blood. This could lead to an increase in the severity of psychotic symptoms.

Perhaps even more dangerously, if medication levels are adjusted for an individual already taking St. John’s wort, stopping the herb could cause these levels to rise, potentially causing dangerous toxic symptoms. Additionall St. John's wort worsens psychotic symptoms for some individuals, typically those with schizophrenia or bipolar disorder diagnoses.

Glycine

Effect: Possible Benefits and Risks

A few studies suggest that the amino acid glycine may augment the action of phenothiazine antipsychotic drugs. It might also augment the action of olanzapine and risperidone, but whether it augments or decreases the effectiveness of clozapine remains unclear.

Ginkgo

Effect: Possible Helpful Interaction

Preliminary evidence suggests that ginkgo might reduce the side effects and increase the efficacy of various antipsychotic medications, including atypical antipsychotic drugs. This may cause seizures in some patients.

Though rare, men taking risperidone (Risperdal) may experience priapism—an erection lasting more than four hours.

Other interactions

Chasteberry, often taken for menopause or infertility, may make some atypical antipsychotics less effective. Ginseng and kava may make these drugs more effective and increase the chances of side effects, particularly when taken with chlorpromazine (Thorazine).

Bibliography

Buchanan, R. W., et al. “The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments.” American Journal of Psychotherapy, vol. 164, 2007, pp. 1593-1602.

De Smet, P. A., and D. J. Touw. “Safety of St. John’s Wort.” The Lancet, vol. 355, 2000, pp. 575-76.

Diaz, P., et al. “Double-Blind, Placebo-Controlled, Crossover Trial of Clozapine Plus Glycine in Refractory Schizophrenia Negative Results.” Journal of Clinical Psychopharmacology, vol. 25, 2005, pp. 277-78.

Evins, A. E., et al. “Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia.” American Journal of Psychiatry, vol. 157, 2000, pp. 826-28.

Heresco-Levy, U., et al. “High-Dose Glycine Added to Olanzapine and Risperidone for the Treatment of Schizophrenia.” Biological Psychiatry, vol. 55, 2004, pp. 165-71.

Kennedy, William K., et al. “Clinically Significant Drug Interactions with Atypical Antipsychotics.” CNSDrugs, vol. 27, no. 12, 2013, pp. 1021-48, doi:10.1007/s40263-013-0114-6.

Meltzer, Herbert, and Erick Gadaleta. "Contrasting Typical and Atypical Antipsychotic Drugs." Focus, vol. 10, no. 1, 28 Jan. 2021, pp. 3-13, doi.org/10.1176/appi.focus.20200051.

Potkin, S. G., et al. “Effect of Clozapine and Adjunctive High-Dose Glycine in Treatment-Resistant Schizophrenia.” American Journal of Psychiatry, vol. 156, 1999, pp. 145-47.

Preston, Claire L. Stockley’s Drug Interactions. 12th ed., Pharmaceutical Press, 2021.

Willner, Keith, et al. "Atypical Antipsychotic Agents." StatPearls, National Library of Medicine, 1 May 2024, www.ncbi.nlm.nih.gov/books/NBK448156. Accessed 20 Sept. 2024.